drugset / Trial / NCT00616993

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)

NCT00616993

Phase 3 Completed 120 enrolled Sirion Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this phase III study is to determine the safety and efficacy of difluprednate in the treatment of inflammation following ocular surgery.

Timeline

Start
2008-01
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Difluprednate Small molecule

Indications

No indication recorded.